checkAd

     113  0 Kommentare Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study - Seite 3

    INVESTOR CONTACT:

    George Jurcic - Head of Investor Relations
    ir@lexariabioscience.com
    Phone: 250-765-6424, ext 202

    Lesen Sie auch

    SOURCE: Lexaria Bioscience Corp.



    View the original press release on accesswire.com


    The Lexaria Bioscience Registered (Old) Stock at the time of publication of the news with a fall of -10,68 % to 0,225USD on Nasdaq OTC stock exchange (12. Januar 2021, 00:20 Uhr).

    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Accesswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study - Seite 3 Human Pilot Study #2 (GLP-1-H24-2) Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces approval has been …